ClearPoint Neuro, Inc. (CLPT)
$
10.46
-0.76 (-7.27%)
Key metrics
Financial statements
Free cash flow per share
-0.4146
Market cap
317.1 Million
Price to sales ratio
9.4405
Debt to equity
0.3349
Current ratio
7.2981
Income quality
0.5025
Average inventory
6.4 Million
ROE
-0.9445
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States, developing and commercializing platforms for minimally invasive surgical procedures in the brain, with the guidance of direct and intra-procedural magnetic resonance imaging (MRI). The company's offerings include the ClearPoint system, which facilitates the insertion of deep brain stimulation electrodes and biopsy needles, as well as the infusion of pharmaceuticals and laser catheters into the brain, alongside the ClearPoint Neuro Navigation System, an MRI suite. Despite its innovative contributions, the company reported a net loss of -$18,914,000.00 indicating challenges in its operations. Additionally, the company incurred depreciation and amortization expenses of $1,903,000.00 reflecting the wear and tear of its assets. The EBITDA is -$17,843,000.00 a key indicator of the company's operational profitability, while the EBITDA ratio is -$0.57 highlighting the company's operational efficiency. The total costs and expenses for the company stand at $51,136,000.00 reflecting its overall spending. Established in 1998 and originally known as MRI Interventions, Inc., the company changed its name to ClearPoint Neuro, Inc. in February 2020 and is headquartered in Solana Beach, California. In the financial landscape, ClearPoint Neuro, Inc. presents itself as an affordable investment opportunity, with the stock priced at $11.85 making it suitable for budget-conscious investors. The stock demonstrates a low average trading volume of 419,061.00 indicating lower market activity. With a market capitalization of $295,651,900.00 the company is classified as a small-cap player and is recognized as a key participant in the Medical - Devices industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its field.
Is ClearPoint Neuro, Inc. (CLPT) a good investment?
Investing in ClearPoint Neuro, Inc. (CLPT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bullish outlook. Always conduct your own research before investing.
What is ClearPoint Neuro, Inc. (CLPT)'s stock forecast?
Analysts predict ClearPoint Neuro, Inc. stock to fluctuate between $9.76 (low) and $19.22 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is ClearPoint Neuro, Inc.'s market capitalization?
As of 2025-08-20, ClearPoint Neuro, Inc.'s market cap is $295,651,900, based on 28,265,000 outstanding shares.
How does ClearPoint Neuro, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, ClearPoint Neuro, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy ClearPoint Neuro, Inc. (CLPT) stock?
To buy ClearPoint Neuro, Inc. (CLPT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CLPT. Place an order (Market, Limit, etc.).
What is the best time to invest in ClearPoint Neuro, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has ClearPoint Neuro, Inc. stock ever split?
ClearPoint Neuro, Inc.'s last stock split was 1:40 on 2016-07-27.
How did ClearPoint Neuro, Inc. perform in the last earnings report?
Revenue: $31,390,000 | EPS: -$0.70 | Growth: -22.22%.
Where can I find ClearPoint Neuro, Inc.'s investor relations reports?
Visit https://www.clearpointneuro.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for ClearPoint Neuro, Inc.?
You can explore historical data from here
What is the all-time high and low for ClearPoint Neuro, Inc. stock?
All-time high: $22.80 (2021-08-09) | All-time low: $4.05 (2023-11-10).
What are the key trends affecting ClearPoint Neuro, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
ClearPoint Neuro's Q2 results were solid; although real upside is likely to be more apparent from 2026 onward. Key catalysts include the launch of GLP services and partner program commercialization, particularly uniQure's Huntington's therapy. Positive partner data and strong system placements could drive ClearPoint's stock higher in 2025.
seekingalpha.com
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Joseph Michael Burnett - President, CEO & Director Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Anderson Schock - B. Riley Securities, Inc., Research Division Operator Greetings, and welcome to the ClearPoint Neuro, Inc.'s Second Quarter 2025 Financial Results Conference Call.
zacks.com
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.16 per share a year ago.
seekingalpha.com
ClearPoint's fundamentals remain strong, despite recent stock weakness. Consumables growth and an expectation of 15-20 system placements in 2025 are illustrative of this strength. The introduction of GLP capabilities and the commercialization of partner programs should lead to stronger growth, beginning in late 2025.
seekingalpha.com
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Joseph Burnett - President and Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Frank Takkinen - Lake Street Capital Markets Anderson Schock - B. Riley Securities Operator Greetings and welcome to ClearPoint Neuro, Inc. First Quarter 2025 Financial Results Conference Call.
zacks.com
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.16 per share a year ago.
accessnewswire.com
Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 13, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2025. First Quarter Highlights Reported record quarterly revenue of $8.5 million, an 11% year-over-year increase compared with the first quarter of 2024; Grew total consumable product revenue by $2.6 million year-over-year, or 104%, including biologics and drug delivery cannulas, SmartFrame® Family Navigation devices, and ClearPoint PRISM® Laser Therapy Applicators; Received FDA Clearance for the ClearPoint 3.0 Software which includes both operating room navigation capability and enhanced laser therapy features.
seekingalpha.com
ClearPoint continues to make progress in relation to its LITT and operating room expansion efforts. More importantly, ClearPoint's partners continue to provide positive news in relation to their therapeutic candidates. It will take time for these tailwinds to impact ClearPoint's financials, but 2026/2027 onwards should see a step change in performance.
seekingalpha.com
ClearPoint's Q4 results were soft, although lumpy growth should be expected given the nature of ClearPoint's business. Neurosurgery growth remains robust, and the expansion of preclinical and clinical services should provide the drug delivery business with a boost within the next 18 months. ClearPoint also continues to control its cash burn, despite continuing to make investments in future growth.
seekingalpha.com
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Anderson Schock - B. Riley Securities Operator Greetings.
See all news
